Australia's most trusted
source of pharma news
Wednesday, 10 December 2025
Posted 10 December 2025 AM
Dr Reddy's and Sydney-based Immutep have signed an exclusive licensing deal for a first-in-class immunotherapy which could see the local biotech receive more than half a billion dollars.
The agreement is for Eftilagimod Alfa (efti) and covers all countries outside North America, Europe, Japan, and Greater China

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.